翰思艾泰生物医药科技（武汉）股份有限公司（股票名称：翰思艾泰-B，股票代码：03378）于2026年7月7日发布公告，披露当日于香港联交所场内回购普通股21,000股，占回购前公司已发行股份总数约0.016%。每股回购价介乎每股28.38港元至29.50港元，合计支付约60.70万港元。回购完成后，公司已发行股份数目由134,429,030股减少至134,408,030股，库藏股数量由1,789,800股增至1,810,800股，发行股份总数维持在136,218,830股不变。
本次回购基于公司于2026年6月24日通过的回购授权，授权总额度为13,469,683股。截至公告日，公司已根据该授权累计回购股份288,800股，约占授权通过当日已发行股份总数的0.2144%。公司确认所有程序均符合香港联合交易所证券上市规则及相关法律法规。本公告由公司董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.